Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 2—February 2006


Borrelia burgdorferi and Anaplasma phagocytophilum Coinfection

Micha Loebermann*, Volker Fingerle†, Matthias Lademann*, Carlos Fritzsche*, and Emil C. Reisinger*Comments to Author 
Author affiliations: *University of Rostock Medical School, Rostock, Germany; †Ludwig-Maximilian-Universität München, Munich, Germany

Main Article


Results of serologic tests at diagnosis and during follow-up*

Time (d) after onset of symptoms Anaplasma (Ehrlichia) phagocytophilum (IFA)†
Borrelia burgdorferi (ELISA)‡
Borrelia burgdorferi (Immunoblot)§
6 Negative (<1:20) Negative (<1:32) Negative Negative Negative Negative
10 ND ND Positive Negative ND ND
28 Positive (1:40) Negative (1:32) Positive Negative Positive Negative
107 Positive (1:20) Negative (<1:32) Positive Negative Positive Negative
380 Negative (<1:20) Negative (<1:32) Equivocal Negative Positive Negative

*Symptoms (fever, headache, myalgia) started 6 days before presentation. IFA, immunofluorescent assay; ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; ND, not done.
†Genzyme Virotech, Germany. Positive titers: IgM >1:20, IgG >1:64.
‡Behring, Germany.
§In-house Immunoblot, Max von Pettenkofer-Institut, Munich, Germany.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO